Genfit S.A Key Executives
This section highlights Genfit S.A's key executives, including their titles and compensation details.
Find Contacts at Genfit S.A
(Showing 0 of )
Genfit S.A Earnings
This section highlights Genfit S.A's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
$3.39
Stock Price
$169.04M
Market Cap
159
Employees
Loos, None
Location
Financial Statements
Access annual & quarterly financial statements for Genfit S.A, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $28.57M | $20.20M | $80.07M | $765.00K | $30.84M |
| Cost of Revenue | $341.00K | $248.00K | $161.00K | $202.00K | $177.00K |
| Gross Profit | $28.22M | $19.95M | $79.91M | $563.00K | $30.66M |
| Gross Profit Ratio | 98.81% | 98.77% | 99.80% | 73.59% | 99.43% |
| Research and Development Expenses | $46.71M | $35.82M | $35.17M | $59.10M | $66.17M |
| General and Administrative Expenses | $8.04M | $16.41M | $16.15M | $14.27M | $17.27M |
| Selling and Marketing Expenses | $- | $992.00K | $1.54M | $11.22M | $13.71M |
| Selling General and Administrative Expenses | $8.04M | $17.40M | $17.69M | $25.49M | $30.97M |
| Other Expenses | $53.00K | $-5.72M | $-4.75M | $-6.23M | $-8.47M |
| Operating Expenses | $54.80M | $47.50M | $48.11M | $78.35M | $88.67M |
| Cost and Expenses | $55.15M | $47.50M | $48.11M | $78.35M | $88.67M |
| Interest Income | $1.71M | $8.21M | $44.78M | $6.54M | $5.22M |
| Interest Expense | $4.62M | $4.76M | $7.12M | $25.30M | $13.11M |
| Depreciation and Amortization | $1.65M | $1.83M | $2.74M | $4.75M | $5.25M |
| EBITDA | $-22.24M | $-23.60M | $34.91M | $-91.14M | $-51.02M |
| EBITDA Ratio | -77.84% | -116.88% | 43.59% | -11913.07% | -165.44% |
| Operating Income | $-26.58M | $-27.55M | $76.74M | $-77.79M | $-57.83M |
| Operating Income Ratio | -93.05% | -136.41% | 95.84% | -10168.76% | -187.53% |
| Total Other Income Expenses Net | $-1.93M | $3.45M | $-7.26M | $-18.75M | $-7.89M |
| Income Before Tax | $-28.51M | $-23.84M | $69.47M | $-101.65M | $-65.72M |
| Income Before Tax Ratio | -99.82% | -118.03% | 86.77% | -13287.45% | -213.11% |
| Income Tax Expense | $380.00K | $-116.00K | $2.21M | $-428.00K | $-576.00K |
| Net Income | $-28.89M | $-23.72M | $67.26M | $-101.22M | $-65.14M |
| Net Income Ratio | -101.15% | -117.45% | 84.00% | -13231.50% | -211.24% |
| EPS | $-0.58 | $-0.48 | $1.50 | $-2.60 | $-1.76 |
| EPS Diluted | $-0.58 | $-0.48 | $1.21 | $-2.60 | $-1.76 |
| Weighted Average Shares Outstanding | 49.82M | 49.67M | 44.74M | 38.86M | 36.99M |
| Weighted Average Shares Outstanding Diluted | 49.82M | 49.67M | 55.61M | 38.86M | 36.99M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | June 30, 2018 | March 31, 2018 | December 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.10M | $30.55M | $17.08M | $2.82M | $11.48M | $7.56M | $6.09M | $5.31M | $8.79M | $80.06M | $11.00K | $643.00K | $122.00K | $30.84M | $1.00K | $7.71M | $2.45M | $5.05M | $1.84M | $2.24M |
| Cost of Revenue | $863.00K | $- | $- | $- | $-3.63M | $- | $- | $- | $-3.35M | $-2.04M | $-3.24M | $-2.17M | $-5.75M | $-2.78M | $-5.35M | $- | $- | $463.50K | $463.50K | $463.50K |
| Gross Profit | $60.24M | $30.55M | $17.08M | $2.82M | $15.11M | $7.56M | $6.09M | $5.31M | $12.14M | $82.10M | $3.25M | $2.81M | $5.87M | $33.62M | $5.35M | $7.71M | $2.45M | $4.58M | $1.38M | $1.77M |
| Gross Profit Ratio | 98.59% | 100.00% | 100.00% | 100.00% | 131.61% | 100.00% | 100.00% | 100.00% | 138.13% | 102.55% | 29581.82% | 437.79% | 4809.02% | 109.01% | 535300.00% | 100.00% | 100.00% | 90.81% | 74.82% | 79.28% |
| Research and Development Expenses | $18.98M | $9.49M | $24.42M | $- | $24.89M | $12.81M | $17.60M | $- | $16.89M | $10.88M | $22.85M | $22.23M | $35.41M | $27.27M | $35.75M | $16.54M | $34.95M | $32.07M | $11.92M | $30.52M |
| General and Administrative Expenses | $10.56M | $5.28M | $8.64M | $- | $9.11M | $4.55M | $8.18M | $- | $8.23M | $8.52M | $7.63M | $6.02M | $8.25M | $7.75M | $9.52M | $4.32M | $4.51M | $4.57M | $3.41M | $5.97M |
| Selling and Marketing Expenses | $390.00K | $195.00K | $356.00K | $- | $520.00K | $260.00K | $532.00K | $- | $460.00K | $756.00K | $783.00K | $1.73M | $9.49M | $10.83M | $2.88M | $3.43M | $717.00K | $- | $- | $- |
| Selling General and Administrative Expenses | $10.95M | $5.48M | $8.17M | $- | $9.50M | $4.81M | $8.44M | $- | $8.46M | $9.26M | $7.13M | $7.47M | $17.43M | $16.51M | $12.29M | $7.74M | $5.23M | $4.57M | $-8.85M | $5.97M |
| Other Expenses | $-29.00K | $-29.00K | $- | $- | $3.00K | $-422.50K | $- | $- | $- | $- | $- | $- | $- | $4.77M | $-24.37M | $-24.37M | $-24.37M | $- | $- | $- |
| Operating Expenses | $29.88M | $14.94M | $32.59M | $- | $34.39M | $17.20M | $26.04M | $- | $25.34M | $20.14M | $29.98M | $29.70M | $52.84M | $39.02M | $48.03M | $-87.00K | $40.21M | $36.39M | $3.07M | $36.69M |
| Cost and Expenses | $29.88M | $14.94M | $33.41M | $- | $35.22M | $17.20M | $26.93M | $- | $26.29M | $21.37M | $31.49M | $32.68M | $54.61M | $41.08M | $51.30M | $22.17M | $40.21M | $36.39M | $19.21M | $36.69M |
| Interest Income | $535.00K | $- | $3.34M | $- | $337.00K | $- | $120.00K | $- | $17.00K | $50.00K | $224.00K | $288.00K | $1.15M | $3.47M | $103.00K | $- | $5.32M | $5.46M | $- | $2.10M |
| Interest Expense | $2.38M | $- | $3.31M | $- | $2.30M | $- | $2.22M | $- | $2.20M | $2.14M | $2.82M | $5.93M | $5.86M | $5.87M | $5.68M | $2.86M | $2.86M | $2.74M | $2.74M | $2.74M |
| Depreciation and Amortization | $848.00K | $424.00K | $631.00K | $-39.59K | $835.00K | $417.50K | $888.00K | $27.08K | $944.00K | $1.23M | $1.51M | $2.98M | $1.77M | $2.06M | $3.27M | $815.75K | $617.00K | $832.00K | $454.75K | $744.00K |
| EBITDA | $32.01M | $16.00M | $-7.36M | $2.82M | $-19.12M | $-9.56M | $-13.04M | $5.31M | $-13.58M | $64.65M | $-26.25M | $-40.37M | $-50.77M | $-6.37M | $-47.83M | $-12.76M | $-37.31M | $-30.72M | $-16.77M | $-33.57M |
| EBITDA Ratio | 52.38% | 52.38% | -43.07% | 100.00% | -166.50% | -126.51% | -213.98% | 100.00% | -154.47% | 80.75% | -238672.73% | -6277.76% | -41613.93% | -20.65% | -4782600.00% | -165.44% | -1524.31% | -608.86% | -910.92% | -1500.67% |
| Operating Income | $31.22M | $15.61M | $-16.33M | $2.82M | $-23.74M | $-9.65M | $6.09M | $5.31M | $-17.50M | $58.68M | $-31.48M | $-32.04M | $-54.49M | $-10.24M | $-51.30M | $-13.57M | $-37.93M | $-31.55M | $-17.22M | $-34.31M |
| Operating Income Ratio | 51.10% | 51.10% | -95.59% | 100.00% | -206.76% | -127.71% | 100.00% | 100.00% | -199.07% | 73.30% | -286154.55% | -4982.27% | -44661.48% | -33.20% | -5130000.00% | -176.02% | -1549.51% | -625.35% | -935.62% | -1533.93% |
| Total Other Income Expenses Net | $-872.00K | $-436.00K | $4.74M | $- | $-247.00K | $-570.50K | $-531.00K | $- | $3.80M | $-94.00K | $34.40M | $-17.24M | $-3.91M | $-4.06M | $-5.47M | $-2.86M | $-5.15M | $-5.24M | $-2.74M | $-2.24M |
| Income Before Tax | $30.35M | $15.18M | $-8.07M | $- | $-23.99M | $-10.22M | $-16.15M | $- | $-13.70M | $61.27M | $2.92M | $-49.27M | $-58.39M | $-14.30M | $-56.77M | $-16.43M | $-43.08M | $-36.80M | $-19.97M | $-36.56M |
| Income Before Tax Ratio | 49.67% | 49.67% | -47.26% | 0.00% | -208.91% | -135.27% | -264.99% | 0.00% | -155.88% | 76.54% | 26536.36% | -7663.30% | -47863.93% | -46.37% | -5677200.00% | -213.11% | -1759.76% | -729.21% | -1084.67% | -1634.29% |
| Income Tax Expense | $39.00K | $19.50K | $-34.00K | $- | $-3.13M | $207.00K | $-2.83M | $- | $-3.30M | $3.07M | $-6.14M | $-1.06M | $-5.38M | $-287.00K | $-5.64M | $-144.00K | $233.00K | $121.00K | $-88.50K | $3.45M |
| Net Income | $30.31M | $15.16M | $-8.04M | $- | $-20.85M | $-10.43M | $-13.32M | $- | $-10.40M | $58.20M | $9.06M | $-48.21M | $-53.01M | $-14.01M | $-51.13M | $-16.29M | $-42.85M | $-36.67M | $-19.88M | $-33.11M |
| Net Income Ratio | 49.61% | 49.61% | -47.06% | 0.00% | -181.62% | -138.01% | -218.54% | 0.00% | -118.30% | 72.70% | 82345.45% | -7497.67% | -43451.64% | -45.44% | -5113200.00% | -211.24% | -1750.25% | -726.81% | -1079.86% | -1480.24% |
| EPS | $0.61 | $0.27 | $-0.16 | $0.00 | $-0.42 | $-0.21 | $-0.27 | $0.00 | $-0.21 | $1.17 | $0.21 | $-1.24 | $-1.37 | $-0.36 | $-1.64 | $-0.44 | $-1.37 | $-1.18 | $-0.64 | $-1.06 |
| EPS Diluted | $0.50 | $0.25 | $-0.16 | $0.00 | $-0.42 | $-0.21 | $-0.27 | $0.00 | $-0.21 | $1.02 | $0.19 | $-1.24 | $-1.37 | $-0.36 | $-1.64 | $-0.44 | $-1.37 | $-1.18 | $-0.64 | $-1.06 |
| Weighted Average Shares Outstanding | 49.69M | 57.19M | 49.70M | 49.70M | 49.70M | 49.65M | 49.68M | 49.67M | 49.67M | 49.68M | 43.69M | 38.80M | 38.81M | 38.81M | 31.18M | 37.01M | 31.17M | 31.17M | 31.17M | 31.17M |
| Weighted Average Shares Outstanding Diluted | 60.36M | 60.36M | 49.70M | 49.70M | 49.70M | 49.70M | 49.68M | 49.67M | 49.67M | 57.09M | 47.67M | 38.80M | 38.81M | 38.81M | 31.18M | 37.01M | 31.17M | 31.17M | 31.17M | 31.17M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $77.79M | $136.00M | $258.76M | $171.03M | $276.75M |
| Short Term Investments | $1.00K | $4.55M | $- | $- | $- |
| Cash and Short Term Investments | $77.79M | $140.55M | $258.76M | $171.03M | $276.75M |
| Net Receivables | $18.53M | $15.91M | $7.24M | $11.92M | $12.03M |
| Inventory | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K |
| Other Current Assets | $16.79M | $2.00M | $2.10M | $1.76M | $13.79M |
| Total Current Assets | $113.11M | $158.46M | $268.10M | $184.72M | $290.75M |
| Property Plant Equipment Net | $7.87M | $8.21M | $9.02M | $11.65M | $16.45M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $48.76M | $43.96M | $174.00K | $791.00K | $920.00K |
| Goodwill and Intangible Assets | $48.76M | $43.96M | $174.00K | $791.00K | $920.00K |
| Long Term Investments | $2.82M | $4.91M | $4.43M | $1.46M | $1.73M |
| Tax Assets | $1.00K | $55.78M | $- | $11.95M | $- |
| Other Non-Current Assets | $1.31M | $-55.78M | $3.00K | $-11.95M | $-1.00K |
| Total Non-Current Assets | $60.76M | $57.08M | $13.62M | $13.90M | $19.10M |
| Other Assets | $-1.00K | $- | $- | $- | $1.00K |
| Total Assets | $173.87M | $215.54M | $281.72M | $198.61M | $309.85M |
| Account Payables | $10.45M | $8.61M | $12.30M | $20.34M | $32.75M |
| Short Term Debt | $7.93M | $5.08M | $2.19M | $4.35M | $4.54M |
| Tax Payables | $23.00K | $4.91M | $5.05M | $633.00K | $489.00K |
| Deferred Revenue | $- | $14.48M | $14.30M | $124.00K | $139.00K |
| Other Current Liabilities | $20.08M | $6.29M | $29.00M | $5.63M | $5.74M |
| Total Current Liabilities | $38.48M | $39.37M | $62.84M | $31.07M | $43.49M |
| Long Term Debt | $62.25M | $70.19M | $72.05M | $181.34M | $179.08M |
| Deferred Revenue Non-Current | $- | $9.71M | $25.82M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $510.00K | $602.00K | $767.00K | $1.19M |
| Other Non-Current Liabilities | $5.19M | $1.23M | $1.32M | $1.37M | $1.86M |
| Total Non-Current Liabilities | $67.44M | $81.64M | $99.79M | $183.71M | $182.29M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $105.92M | $121.01M | $162.62M | $214.78M | $225.79M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $12.46M | $12.46M | $12.45M | $9.72M | $9.71M |
| Retained Earnings | $-389.79M | $-361.27M | $-337.82M | $-404.85M | $-303.48M |
| Accumulated Other Comprehensive Income Loss | $996.00K | $-1.34M | $22.00K | $-92.00K | $14.00K |
| Other Total Stockholders Equity | $444.29M | $444.68M | $444.44M | $379.06M | $377.82M |
| Total Stockholders Equity | $67.95M | $94.53M | $119.10M | $-16.16M | $84.06M |
| Total Equity | $67.95M | $94.53M | $119.10M | $-16.16M | $84.06M |
| Total Liabilities and Stockholders Equity | $173.87M | $215.54M | $281.72M | $198.61M | $309.85M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $173.87M | $215.54M | $281.72M | $198.61M | $309.85M |
| Total Investments | $2.82M | $9.46M | $4.43M | $1.46M | $1.73M |
| Total Debt | $70.18M | $75.28M | $74.23M | $185.69M | $183.62M |
| Net Debt | $-7.61M | $-60.73M | $-184.52M | $14.66M | $-93.13M |
Balance Sheet Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $61.65M | $61.65M | $77.79M | $77.79M | $111.83M | $111.83M | $136.00M | $209.12M | $258.76M | $104.38M | $171.03M | $225.72M | $276.75M | $281.92M | $207.24M | $238.01M | $273.82M | $126.29M | $152.28M | $94.64M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $4.55M | $- | $-785.00K | $- | $- | $- | $-704.00K | $- | $- | $28.00K | $31.00K | $31.00K | $- | $26.00K |
| Cash and Short Term Investments | $61.65M | $61.65M | $77.79M | $77.79M | $111.83M | $111.83M | $140.55M | $209.12M | $258.76M | $104.38M | $171.03M | $225.72M | $276.75M | $281.92M | $207.24M | $238.01M | $273.82M | $126.29M | $152.28M | $94.64M |
| Net Receivables | $61.47M | $61.47M | $32.71M | $18.53M | $20.18M | $2.79M | $15.91M | $756.00K | $7.24M | $13.84M | $11.92M | $308.00K | $12.03M | $3.02M | $25.00K | $65.00K | $7.96M | $13.34M | $8.39M | $9.09M |
| Inventory | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $14.00K | $17.00K |
| Other Current Assets | $13.26M | $13.26M | $2.62M | $16.79M | $2.58M | $19.97M | $2.00M | $13.65M | $2.10M | $3.06M | $1.76M | $12.17M | $13.79M | $19.45M | $10.85M | $15.34M | $1.79M | $1.75M | $1.31M | $1.08M |
| Total Current Assets | $136.38M | $136.38M | $113.11M | $113.11M | $134.59M | $134.59M | $158.46M | $223.53M | $268.10M | $121.28M | $184.72M | $238.20M | $290.75M | $304.39M | $218.12M | $253.42M | $283.57M | $141.38M | $162.00M | $104.83M |
| Property Plant Equipment Net | $8.06M | $8.06M | $7.87M | $7.87M | $8.14M | $8.14M | $8.21M | $8.55M | $9.02M | $10.33M | $11.65M | $15.51M | $16.45M | $17.25M | $7.76M | $6.93M | $6.32M | $4.68M | $3.01M | $1.75M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $46.95M | $46.95M | $48.76M | $48.76M | $46.18M | $46.18M | $43.96M | $149.00K | $174.00K | $704.00K | $791.00K | $893.00K | $920.00K | $1.02M | $795.00K | $635.00K | $636.00K | $778.00K | $667.00K | $554.00K |
| Goodwill and Intangible Assets | $46.95M | $46.95M | $48.76M | $48.76M | $46.18M | $46.18M | $43.96M | $149.00K | $174.00K | $704.00K | $791.00K | $893.00K | $920.00K | $1.02M | $795.00K | $635.00K | $636.00K | $778.00K | $667.00K | $554.00K |
| Long Term Investments | $1.89M | $1.89M | $4.12M | $2.82M | $3.62M | $3.62M | $4.91M | $4.08M | $4.43M | $1.40M | $1.46M | $843.00K | $1.73M | $1.05M | $770.00K | $216.00K | $267.00K | $125.00K | $109.00K | $142.00K |
| Tax Assets | $- | $- | $-1.00K | $- | $1.37M | $- | $55.78M | $- | $- | $- | $11.95M | $- | $- | $18.27M | $2.03M | $514.00K | $2.38M | $447.00K | $- | $513.00K |
| Other Non-Current Assets | $1.50M | $1.50M | $-1.00K | $1.30M | $1.00K | $1.37M | $-55.78M | $733.00K | $3.00K | $-1.00K | $-11.95M | $754.00K | $-1.00K | $-18.27M | $1.00K | $1.92M | $1.00K | $-1.00K | $433.00K | $4.00K |
| Total Non-Current Assets | $58.39M | $58.39M | $60.76M | $60.76M | $59.31M | $59.31M | $57.08M | $13.52M | $13.62M | $12.43M | $13.90M | $18.00M | $19.10M | $19.32M | $11.36M | $10.22M | $9.61M | $6.03M | $4.22M | $2.96M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $1.00K | $-1.00K | $- | $- | $- | $- | $-1.00K | $1.00K |
| Total Assets | $194.78M | $194.78M | $173.87M | $173.87M | $193.91M | $193.91M | $215.54M | $237.05M | $281.72M | $133.71M | $198.61M | $256.20M | $309.85M | $323.71M | $229.48M | $263.63M | $293.18M | $147.40M | $166.21M | $107.79M |
| Account Payables | $8.04M | $8.04M | $10.45M | $10.45M | $15.88M | $15.88M | $8.61M | $10.23M | $12.30M | $23.17M | $20.34M | $30.08M | $32.75M | $35.80M | $32.65M | $24.85M | $19.05M | $14.95M | $13.34M | $8.03M |
| Short Term Debt | $8.02M | $8.02M | $7.93M | $7.92M | $7.75M | $7.75M | $5.08M | $2.25M | $2.19M | $2.87M | $4.35M | $4.53M | $4.54M | $4.37M | $3.16M | $3.27M | $3.16M | $1.59M | $1.25M | $1.29M |
| Tax Payables | $- | $- | $23.00K | $- | $5.98M | $- | $4.91M | $5.24M | $5.05M | $173.00K | $633.00K | $388.00K | $489.00K | $789.00K | $287.00K | $392.00K | $260.00K | $178.00K | $211.00K | $139.00K |
| Deferred Revenue | $- | $- | $11.69M | $- | $11.24M | $- | $14.48M | $13.67M | $14.30M | $122.00K | $124.00K | $141.00K | $139.00K | $1.00K | $1.00K | $2.00K | $1.00K | $1.00K | $1.00K | $16.00K |
| Other Current Liabilities | $20.37M | $20.37M | $8.39M | $20.11M | $4.80M | $22.03M | $6.29M | $3.90M | $29.00M | $4.62M | $5.63M | $6.56M | $5.42M | $6.27M | $3.15M | $3.02M | $4.63M | $2.58M | $2.76M | $2.11M |
| Total Current Liabilities | $36.43M | $36.43M | $38.48M | $38.48M | $45.66M | $45.66M | $39.37M | $35.29M | $62.84M | $30.96M | $31.07M | $41.71M | $43.49M | $47.23M | $39.25M | $31.53M | $27.11M | $19.30M | $17.56M | $11.58M |
| Long Term Debt | $59.79M | $59.79M | $62.25M | $62.25M | $67.67M | $67.67M | $70.19M | $72.50M | $72.05M | $68.06M | $181.34M | $180.10M | $179.08M | $175.76M | $166.43M | $160.69M | $160.59M | $6.92M | $5.00M | $4.70M |
| Deferred Revenue Non-Current | $- | $- | $3.75M | $- | $4.75M | $- | $9.71M | $18.28M | $25.82M | $-38.44M | $-152.07M | $-146.40M | $-142.84M | $1.29M | $1.00K | $1.00K | $2.00K | $3.00K | $3.00K | $4.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $455.00K | $- | $491.00K | $- | $510.00K | $647.00K | $602.00K | $608.00K | $767.00K | $1.06M | $1.19M | $1.49M | $1.77M | $433.00K | $321.00K | $893.00K | $9.59M | $782.00K |
| Other Non-Current Liabilities | $1.20M | $1.20M | $978.00K | $5.19M | $814.00K | $6.05M | $1.23M | $1.17M | $1.32M | $1.52M | $1.60M | $1.95M | $2.02M | $1.90M | $2.86M | $979.00K | $936.00K | $892.00K | $852.00K | $5.00K |
| Total Non-Current Liabilities | $60.98M | $60.98M | $67.44M | $67.44M | $73.72M | $73.72M | $81.64M | $92.59M | $99.79M | $70.18M | $183.71M | $183.11M | $182.29M | $180.44M | $169.29M | $162.10M | $161.85M | $7.81M | $5.86M | $5.48M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $97.41M | $97.41M | $105.92M | $105.92M | $119.39M | $119.39M | $121.01M | $127.88M | $162.62M | $101.15M | $214.78M | $224.82M | $225.79M | $227.67M | $208.54M | $193.64M | $188.95M | $27.11M | $23.42M | $17.06M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $- | $- | $- |
| Common Stock | $12.48M | $12.48M | $12.46M | $12.46M | $12.46M | $12.46M | $12.46M | $12.45M | $12.45M | $11.44M | $9.72M | $9.71M | $9.71M | $9.71M | $7.80M | $7.79M | $7.79M | $7.79M | $7.79M | $6.59M |
| Retained Earnings | $-360.35M | $-360.35M | $-390.76M | $-389.79M | $-381.76M | $-380.87M | $-361.27M | $-348.06M | $-337.82M | $-395.79M | $-404.85M | $-356.67M | $-303.48M | $-290.15M | $-238.42M | $-195.65M | $-161.13M | $-124.94M | $-102.32M | $-81.29M |
| Accumulated Other Comprehensive Income Loss | $-454.00K | $-454.00K | $996.00K | $995.00K | $-1.14M | $-1.14M | $-1.34M | $181.00K | $22.00K | $-52.00K | $-92.00K | $7.00K | $14.00K | $7.00K | $6.00K | $-1.00K | $-8.00K | $4.00K | $21.00K | $11.00K |
| Other Total Stockholders Equity | $445.69M | $445.69M | $445.26M | $444.29M | $444.07M | $444.07M | $444.68M | $444.59M | $444.44M | $416.96M | $379.06M | $378.33M | $377.82M | $376.48M | $251.55M | $257.85M | $251.81M | $237.43M | $237.31M | $165.42M |
| Total Stockholders Equity | $97.36M | $97.36M | $67.95M | $67.95M | $74.52M | $74.52M | $94.53M | $109.17M | $119.10M | $32.57M | $-16.16M | $31.38M | $84.06M | $96.04M | $20.94M | $70.00M | $104.23M | $120.29M | $142.80M | $90.73M |
| Total Equity | $97.36M | $97.36M | $67.95M | $67.95M | $74.52M | $74.52M | $94.53M | $109.17M | $119.10M | $32.57M | $-16.16M | $31.38M | $84.06M | $96.04M | $20.94M | $70.00M | $104.23M | $120.29M | $142.80M | $90.73M |
| Total Liabilities and Stockholders Equity | $194.78M | $194.78M | $173.87M | $173.87M | $193.91M | $193.91M | $215.54M | $237.05M | $281.72M | $133.71M | $198.61M | $256.20M | $309.85M | $323.71M | $229.48M | $263.63M | $293.18M | $147.40M | $166.21M | $107.79M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $194.78M | $194.78M | $173.87M | $173.87M | $193.91M | $193.91M | $215.54M | $237.05M | $281.72M | $133.71M | $198.61M | $256.20M | $309.85M | $323.71M | $229.48M | $263.63M | $293.18M | $147.40M | $166.21M | $107.79M |
| Total Investments | $1.89M | $1.89M | $4.12M | $2.82M | $3.62M | $3.62M | $9.46M | $4.08M | $3.65M | $1.40M | $1.46M | $843.00K | $1.02M | $1.05M | $770.00K | $216.00K | $267.00K | $125.00K | $109.00K | $142.00K |
| Total Debt | $67.80M | $67.80M | $70.18M | $70.18M | $75.42M | $75.42M | $75.28M | $74.74M | $74.23M | $70.93M | $185.69M | $184.64M | $183.62M | $182.03M | $169.59M | $163.96M | $163.75M | $8.50M | $6.25M | $5.99M |
| Net Debt | $6.16M | $6.16M | $-7.61M | $-7.61M | $-36.40M | $-36.40M | $-60.73M | $-134.37M | $-184.52M | $-33.45M | $14.66M | $-41.09M | $-93.13M | $-99.89M | $-37.66M | $-74.05M | $-110.07M | $-117.78M | $-146.03M | $-88.66M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-28.89M | $-23.72M | $67.26M | $-101.22M | $-65.14M |
| Depreciation and Amortization | $1.65M | $1.83M | $2.74M | $3.56M | $5.41M |
| Deferred Income Tax | $380.00K | $-116.00K | $2.21M | $-428.00K | $-576.00K |
| Stock Based Compensation | $578.00K | $245.00K | $470.00K | $1.24M | $1.66M |
| Change in Working Capital | $-27.82M | $-54.79M | $59.68M | $-11.13M | $-356.00K |
| Accounts Receivables | $-17.42M | $-8.56M | $4.34M | $318.00K | $-1.64M |
| Inventory | $17.42M | $- | $- | $- | $- |
| Accounts Payables | $-10.40M | $-46.23M | $55.34M | $-11.45M | $1.28M |
| Other Working Capital | $-17.42M | $- | $- | $- | $- |
| Other Non Cash Items | $-1.33M | $3.91M | $-32.45M | $11.61M | $11.33M |
| Net Cash Provided by Operating Activities | $-55.43M | $-72.64M | $99.92M | $-96.37M | $-47.68M |
| Investments in Property Plant and Equipment | $-414.00K | $- | $-537.00K | $-900.00K | $-2.03M |
| Acquisitions Net | $- | $-41.52M | $309.00K | $- | $2.52M |
| Purchases of Investments | $-12.00K | $-5.01M | $-3.15M | $-66.00K | $-160.00K |
| Sales Maturities of Investments | $4.56M | $- | $-309.00K | $- | $-2.52M |
| Other Investing Activities | $-1.90M | $271.00K | $308.00K | $-66.00K | $2.52M |
| Net Cash Used for Investing Activities | $2.23M | $-46.27M | $-3.38M | $-966.00K | $327.00K |
| Debt Repayment | $-4.61M | $-1.75M | $-35.05M | $-1.94M | $-1.88M |
| Common Stock Issued | $- | $5.00K | $27.97M | $7.00K | $126.49M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-493.00K | $-2.04M | $-1.83M | $-6.32M | $-7.74M |
| Net Cash Used Provided by Financing Activities | $-5.10M | $-3.79M | $-8.92M | $-8.26M | $116.86M |
| Effect of Forex Changes on Cash | $80.00K | $-65.00K | $105.00K | $-126.00K | $1.00K |
| Net Change in Cash | $-58.21M | $-122.75M | $87.73M | $-105.72M | $69.51M |
| Cash at End of Period | $77.79M | $136.00M | $258.76M | $171.03M | $276.75M |
| Cash at Beginning of Period | $136.00M | $258.76M | $171.03M | $276.75M | $207.24M |
| Operating Cash Flow | $-55.43M | $-72.64M | $99.92M | $-96.37M | $-47.68M |
| Capital Expenditure | $-2.49M | $- | $-537.00K | $-900.00K | $-2.03M |
| Free Cash Flow | $-57.92M | $-72.64M | $99.38M | $-97.27M | $-49.71M |
Cash Flow Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | June 30, 2018 | March 31, 2018 | December 31, 2017 | June 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $30.31M | $15.16M | $-8.04M | $-4.02M | $-20.85M | $-10.43M | $-13.32M | $-10.40M | $58.20M | $9.06M | $-48.21M | $-53.01M | $-14.01M | $-51.13M | $-16.29M | $-42.85M | $-36.67M | $-19.88M | $-33.11M | $-22.61M |
| Depreciation and Amortization | $863.00K | $427.00K | $786.00K | $409.50K | $835.00K | $417.50K | $888.00K | $944.00K | $1.23M | $1.51M | $2.98M | $1.77M | $2.06M | $3.27M | $815.75K | $617.00K | $832.00K | $454.75K | $744.00K | $370.00K |
| Deferred Income Tax | $- | $- | $-22.13M | $- | $-9.20M | $- | $-16.35M | $-42.35M | $58.66M | $-4.94M | $-17.30M | $-4.55M | $-980.00K | $-144.00K | $-144.00K | $-144.00K | $5.39M | $- | $-3.43M | $96.00K |
| Stock Based Compensation | $167.00K | $167.00K | $304.00K | $152.00K | $274.00K | $137.00K | $97.00K | $148.00K | $253.00K | $217.00K | $723.00K | $513.00K | $1.30M | $356.00K | $- | $516.00K | $271.00K | $- | $149.00K | $129.00K |
| Change in Working Capital | $-39.41M | $-19.71M | $-12.56M | $-6.28M | $-7.26M | $-2.43M | $-14.48M | $-40.31M | $61.38M | $-1.70M | $-10.63M | $-503.00K | $4.44M | $-4.80M | $-89.00K | $4.93M | $-5.66M | $2.58M | $3.28M | $-5.37M |
| Accounts Receivables | $-39.41M | $-19.71M | $-12.56M | $-6.28M | $-4.86M | $-2.43M | $-3.49M | $-5.07M | $7.56M | $-3.22M | $-1.21M | $1.52M | $8.46M | $-10.10M | $-410.00K | $4.93M | $-5.66M | $-181.00K | $3.28M | $-5.38M |
| Inventory | $- | $- | $12.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.00K |
| Accounts Payables | $-5.57M | $- | $-8.00M | $- | $-2.40M | $- | $-10.98M | $-35.24M | $53.82M | $1.52M | $-9.42M | $-2.03M | $-4.02M | $5.31M | $321.00K | $321.00K | $2.76M | $2.76M | $2.76M | $1.84M |
| Other Working Capital | $5.57M | $- | $-12.56M | $- | $- | $- | $- | $- | $- | $- | $- | $-1 | $-1 | $- | $- | $-321.00K | $-2.76M | $- | $-2.76M | $-3.69M |
| Other Non Cash Items | $-3.12M | $-1.64M | $-10.85M | $-5.44M | $10.36M | $-235.50K | $17.02M | $43.43M | $-53.00M | $-32.80M | $18.34M | $7.19M | $1.82M | $13.90M | $3.37M | $12.25M | $9.68M | $2.63M | $4.99M | $1.59M |
| Net Cash Provided by Operating Activities | $-11.19M | $-5.59M | $-30.36M | $-15.18M | $-25.84M | $-12.54M | $-26.14M | $-48.54M | $126.72M | $-28.64M | $-54.10M | $-48.59M | $-5.37M | $-50.09M | $-11.92M | $-24.53M | $-31.55M | $-14.02M | $-23.95M | $-25.90M |
| Investments in Property Plant and Equipment | $-737.00K | $-368.50K | $-414.00K | $-207.00K | $-2.00M | $- | $- | $- | $-516.00K | $-21.00K | $-115.00K | $-785.00K | $-1.97M | $-65.00K | $-507.50K | $-1.96M | $-983.00K | $-734.50K | $-1.68M | $-1.12M |
| Acquisitions Net | $- | $- | $49.00K | $- | $123.00K | $- | $-41.50M | $250.00K | $85.00K | $224.00K | $- | $- | $2.52M | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-28.00K | $- | $-12.00K | $- | $-2.68M | $- | $-4.56M | $-449.00K | $-3.15M | $-236.00K | $-17.00K | $-49.00K | $-32.00K | $-128.00K | $-40.00K | $-40.00K | $-262.50K | $-262.50K | $-262.50K | $-40.75K |
| Sales Maturities of Investments | $- | $- | $3.00K | $- | $4.56M | $- | $- | $- | $3.06M | $12.00K | $- | $- | $-2.48M | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $78.00K | $25.00K | $-34.00K | $-17.00K | $2.68M | $1.34M | $-4.54M | $-199.00K | $-3.08M | $236.00K | $-17.00K | $-49.00K | $2.48M | $-128.00K | $547.50K | $-1.00M | $-48.00K | $997.00K | $-137.00K | $-11.00K |
| Net Cash Used for Investing Activities | $-687.00K | $-343.50K | $-448.00K | $-224.00K | $2.68M | $1.34M | $-46.07M | $-199.00K | $-3.59M | $215.00K | $-132.00K | $-834.00K | $520.00K | $-193.00K | $-547.50K | $-2.96M | $-1.03M | $-997.25K | $-1.82M | $-1.13M |
| Debt Repayment | $-3.69M | $- | $- | $- | $-464.00K | $- | $- | $-310.00K | $- | $-37.12M | $1.81M | $-1.60M | $- | $-1.51M | $- | $- | $-161.00K | $- | $- | $1.07M |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $5.00K | $- | $27.97M | $- | $7.00K | $- | $50.00K | $126.48M | $31.62M | $31.62M | $- | $- | $- | $4.99M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-537.00K | $-2.11M | $-3.33M | $-1.67M | $-1.30M | $-882.00K | $-1.85M | $-1.63M | $31.05M | $-1.01M | $-5.24M | $-3.23M | $-4.92M | $126.48M | $-31.15M | $-3.28M | $-3.07M | $500.00K | $173.31M | $-25.00K |
| Net Cash Used Provided by Financing Activities | $-4.22M | $-2.11M | $-3.33M | $-1.67M | $-995.00K | $-882.00K | $-840.00K | $-903.00K | $31.05M | $-38.13M | $-335.00K | $-1.60M | $-321.00K | $124.97M | $31.15M | $-3.28M | $-3.23M | $-500.00K | $173.31M | $1.04M |
| Effect of Forex Changes on Cash | $-21.50K | $-21.50K | $100.00K | $50.00K | $-20.00K | $-10.00K | $-66.00K | $258.76M | $193.00K | $-88.00K | $-126.00K | $276.75M | $-276.75M | $-1.31M | $-1.31M | $-1.31M | $-1.13M | $-1.13M | $-1.13M | $39.01M |
| Net Change in Cash | $- | $- | $-34.04M | $-111.83M | $-24.18M | $- | $-73.11M | $-49.64M | $154.38M | $-66.65M | $-54.69M | $-51.03M | $-5.17M | $230.11M | $17.38M | $-168.82M | $169.56M | $-16.64M | $-74.48M | $88.22M |
| Cash at End of Period | $61.65M | $- | $77.79M | $- | $111.83M | $- | $136.00M | $209.12M | $258.76M | $104.38M | $171.03M | $225.72M | $276.75M | $281.92M | $69.19M | $69.19M | $238.01M | $51.81M | $51.81M | $126.29M |
| Cash at Beginning of Period | $- | $- | $111.83M | $111.83M | $136.00M | $- | $209.12M | $258.76M | $104.38M | $171.03M | $225.72M | $276.75M | $281.92M | $51.81M | $51.81M | $238.01M | $68.45M | $68.45M | $126.29M | $38.07M |
| Operating Cash Flow | $-11.19M | $-5.59M | $-30.36M | $-15.18M | $-25.84M | $-12.54M | $-26.14M | $-48.54M | $126.72M | $-28.64M | $-54.10M | $-48.59M | $-5.37M | $-50.09M | $-11.92M | $-24.53M | $-31.55M | $-14.02M | $-23.95M | $-25.90M |
| Capital Expenditure | $-737.00K | $-368.50K | $-414.00K | $-207.00K | $-2.00M | $- | $- | $- | $-516.00K | $-21.00K | $-115.00K | $-785.00K | $-1.97M | $-65.00K | $-507.50K | $-1.96M | $-983.00K | $-734.50K | $-1.68M | $-1.12M |
| Free Cash Flow | $-11.92M | $-5.96M | $-30.77M | $-15.38M | $-27.84M | $-12.54M | $-26.14M | $-48.54M | $126.21M | $-28.66M | $-54.21M | $-49.38M | $-7.34M | $-50.16M | $-12.43M | $-26.49M | $-32.53M | $-14.75M | $-25.63M | $-27.02M |
Genfit S.A Dividends
Explore Genfit S.A's dividend history, including dividend yield, payout ratio, and historical payments.
Genfit S.A News
Read the latest news about Genfit S.A, including recent articles, headlines, and updates.
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), is pleased to announce the successful completion of its royalty financing transaction with HealthCare Royalty (“HCRx”) and the results of the repurchase offer to 2025 OCEANEs holders.
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces the results of the bondholders' vote at the general meeting of the 2025 OCEANEs holders which took place this Monday, March 10, 2025 at 2:30pm (Paris time): all resolutions proposed by the Company were approved.
GENFIT Announces Revenues and Cash Position as of December 31, 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 27, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2024 and revenues for 2024
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025.
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 14, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the amendment of the final terms of the 2025 OCEANEs repurchase proposal and the consent fee that would be paid to the holders of 2025 OCEANEs still outstanding after cancellation of repurchased 2025 OCEANEs.
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today outlines the design of new clinical trials within its Acute on-Chronic Liver Failure (ACLF) pipeline, with several clinical data readouts by end of 2025.
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million, and debt overhang resolution plan.
GENFIT Announces 2025 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025.
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead of The Liver Meeting 2024®2.
GENFIT Reports Third Quarter 2024 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of September 30, 2024 and revenue for the first nine months of 20241.
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA. This follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on July 26, 2024 and the U.S. FDA Accelerated Approval on June, 10, 2024 .
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen's Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA.
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration (FDA) accelerated approval of Iqirvo1 (elafibranor)2 80 mg tablets – as unveiled today by Ipsen (Euronext: IPN; ADR: IPSEY) – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024.
Genfit: Under The Radar Biotech With Upcoming Catalysts
Genfit S.A. has a PDUFA date of June 10, 2024, by which time the FDA will decide upon whether elafibranor should be approved to treat patients with primary biliary cholangitis. European marketing approval of elafibranor for treatment of patients with primary biliary cholangitis is also possible; Expected to happen in 2nd half of 2024. Interim results from the phase 2 UNVEIL-IT study, using VS-01 for the treatment of patients with acute chronic liver failure, expected in the 2nd half of 2024.
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 22, 2024. The quorum on first convening amounted to 27.25% and shareholders approved all of the resolutions.
GENFIT Reports First Quarter 2024 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.1
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023).
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 10:00am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF ; filing n° D.24-0246) and its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
Lille, France; Cambridge, MA; Zurich, Switzerland; April 4, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2023. A summary of the consolidated financial statements is included below.
GENFIT Announces Revenues and Cash Position as of December 31, 2023
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2023 and revenues for 2023.
GENFIT Announces 2024 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024.
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 8, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its revised outlook for 2024 and reflects on recent progress.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GNFT.